Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label multicenter study of orelabrutinib in B-cell malignancies
MOH_2022-01-13_010550Phase 2Not yet recruiting
- Sponsor
- InnoCare Pharma
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of orelabrutinib in B-cell malignancy, mantle cell lymphoma (MCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and 2 more (2 arms), sponsored by InnoCare Pharma. Primary endpoints: Safety, Tolerability and 2 more. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
orelabrutinib
03
Conditions
B-cell malignancymantle cell lymphoma (MCL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on MOH_2022-01-13_010550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-01-13_010550.